RecruitingPhase 2NCT07586826

Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors

Studying Primary peritoneal tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University People's Hospital
Principal Investigator
Xiaohui Zhang, MD, M.D
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology
Intervention
Romiplostim N01(drug)
Enrollment
220 target
Eligibility
18 years · All sexes
Timeline
2025 – 2027

Study locations (1)

Collaborators

Peking University Cancer Hospital and Institute · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Peking University International Hospital · Shanxi Province Cancer Hospital · Henan Provincial People's Hospital · China-Japan Union Hospital, Sun Yat-sen University Cancer Center · Hebei Medical University Fourth Hospital · Tianjin Medical University Cancer Institute and Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07586826 on ClinicalTrials.gov

Other trials for Primary peritoneal tumor

Additional recruiting or active studies for the same condition.

See all trials for Primary peritoneal tumor →

← Back to all trials